 |
Publisher: Peytchinski, Gospodin Iliev
ISSN: 1312 773X (Online)
Issue: 2016, vol. 22, issue 1
Subject Area: Medicine - Hematology
Pages: 1083-1085
DOI: http://dx.doi.org/10.5272/jimab.2016221.1083
Published online: 29 March 2016
J of IMAB 2016 Jan-Mar;22(1):1083-1085
IMPACT OF THE IMPAIRED IRON HOMEOSTASIS ON THE PATHOGENESIS OF ANEMIA IN PRIMARY MYELOFIBROSIS
Liana Gercheva, 
, Stela Dimitrova, Ilina Micheva.
Clinic of Hematology, Medical University, Varna, University Hospital "St. Marina", Varna, Bulgaria.
ABSTRACT:
Anemia is a well established prognostic factor in primary myelofibrosis (PMF). Recent data suggests that markers of abnormal iron homeostasis, which are known to be affected by both iron overload and inflammation, may be involved in the pathogenesis of anemia in PMF.
Aim: To evaluate the relation between anemia, bone marrow fibrosis, prognostic score, survival and parameters of iron metabolism.
Materials and methods: We studied 72 patients with PMF. The following parameters were analyzed: degree of bone marrow fibrosis, hemoglobin level, MCV, components of iron homeostasis (total iron binding capacity (TIBC), ferritin, serum iron). The prognostic score was determined according to IPSS and DIPSS. Statistical analysis was performed by SPSS version 19.
Results: We found significant correlation between the level of hemoglobin and degree of bone marrow fibrosis and prognostic score. The MCV was analyzed in 56 of the patients and was found low in 9,5 % of them. However, there was no significant correlation between degree of fibrosis and the lower MCV. We found significant straight correlation between degree of fibrosis, serum ferritin level (p=0.006) and TIBC (p=0.018). In univariate analysis, significant feedback correlation was established between hemoglobin and serum ferritin level.
Conclusion: Our results reveal the possible role of the impaired iron metabolism in the pathogenesis of anemia in PMF. Further studies are needed in order to elucidate the precise mechanisms of this process.
Key words: Primary myelofibrosis, anemia, iron metabolism,
- Download FULL TEXT /PDF 630 KB/
Please cite this article in PubMed Style or AMA (American Medical Association) Style:
Gercheva L, Dimitrova S, Micheva I. Impact of the impared iron homeostasis on the pathogenesis of anemia in Primary myelofibrosis. J of IMAB. 2016 Jan-Mar;22(1):1083-1085.
DOI: http://dx.doi.org/10.5272/jimab.2016221.1083.
Correspondence to: Assoc. Prof. Liana T. Gercheva, MD, PhD; Head of Clinic of Hematology University Hospital St. Marina – Varna; 1, Hristo Smirnenski str, 9002 Varna, Bulgaria; E-mail: lianagercheva@gmail.com
REFERENCES:
1. Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaiya R, et al. One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc. 2012 Jan;87(1):25-33. [PubMed] [CrossRef]
2. Gangat N, Caramazza D, ;Vaidya R, George G, Begna K, Schwager S et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011 Feb 1;29(4):392-7. [PubMed] [CrossRef]
3. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. et al. Circulating interleukin (IL)-8,IL-2R, IL-12 and IL-15 levels sre independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study. J ClinOncol. 2011;29:1356-1363. [PubMed] [CrossRef]
4. Pardanani A, Finke Chr, Abdelrahman R, Lasho T, Tefferi A Associations and prognostic interctions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis, Am J Hematology. 2013 Apr;88(4):312-316. [PubMed] [CrossRef]
5. Strati P, Pemmarau N, Estrov Z, Cardanas-Turanzas M, Pierce Sh, Newberry KJ, et al. Clinical significance of microcytosis in patients with primary myelofibrosis. Leukemia Research. 2014 Oct;38(10):1212-1216. [PubMed] [CrossRef].
Received: 15 December 2015
Published online: 29 March 2016